<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02191852</url>
  </required_header>
  <id_info>
    <org_study_id>1135.4</org_study_id>
    <nct_id>NCT02191852</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Seresis® in the Skin in Healthy Young Female Volunteers</brief_title>
  <official_title>A Pharmacokinetic Study on the Antioxidant Activity of Seresis® in the Skin: an Open, Uncontrolled, Non-randomized Intra-individual Pilot Trial in Healthy, Young Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to evaluate the total antioxidant capacity of Seresis® (with Thiobarbituric acid&#xD;
      reactive substances (TBARS) assays)) in the skin; as well as in buccal mucosa cells (BMCs)&#xD;
      and in plasma, compared to baseline values; furthermore to detect the quantitative enrichment&#xD;
      of individual antioxidant compounds contained in the product and to investigate whether or&#xD;
      not some of them accumulate in target tissues such as skin, BMCs and plasma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 1999</start_date>
  <primary_completion_date type="Actual">October 1999</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total antioxidant capacity in skin biopsies</measure>
    <time_frame>Day 0, Day 112</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total antioxidant capacity in skin biopsies</measure>
    <time_frame>Day 0, Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total antioxidant capacity in buccal mucosa cells (BMCs)</measure>
    <time_frame>Day 0, 14, 28, 42, 56, 84, 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total antioxidant capacity in plasma</measure>
    <time_frame>Day 0, 14, 28, 42, 56, 84, 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of vitamin C and E and carotenoids</measure>
    <time_frame>Day 0, 14, 28, 42, 56, 84, 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of vitamin E and carotenoids in skin biopsies</measure>
    <time_frame>Day 0, 56, 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of vitamin E and carotenoids in BMCs</measure>
    <time_frame>Day 0, 14, 28, 42, 56, 84, 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 119 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by volunteers on a 4-point scale</measure>
    <time_frame>Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in laboratory parameters</measure>
    <time_frame>up to 112 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Seresis®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 capsules per day for a period of 16 consecutive weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seresis®</intervention_name>
    <arm_group_label>Seresis®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy female volunteers between 18 and 30 years&#xD;
&#xD;
          -  With skin type II or skin type III&#xD;
&#xD;
          -  BMI &lt; 25&#xD;
&#xD;
          -  Non-smokers&#xD;
&#xD;
          -  Volunteers who have given their written informed consent according to Good Clinical&#xD;
             Practice (GCP) and local regulations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any serious disorder that may interfere with her participation to the trial and&#xD;
             evaluation of the safety of the test drug (e.g. liver and/or renal disease,&#xD;
             hypervitaminosis A, psychic disorder, etc.), and/or treatment with chronic medication&#xD;
&#xD;
          -  Pre-treatment (less than 2 weeks prior to inclusion in this trial) and/or concomitant&#xD;
             treatment with any drug that may influence the trial symptomatology and may interfere&#xD;
             with evaluation of the safety of the test drug (e.g. vitamins and minerals&#xD;
             supplementation)&#xD;
&#xD;
          -  Relevant allergy or known hypersensitivity to the investigational drug or its&#xD;
             excipients&#xD;
&#xD;
          -  High performance sports&#xD;
&#xD;
          -  Alcohol and drug abuse according to Diagnostic and Statistics Manual, Version IV&#xD;
             (DSM-IV)&#xD;
&#xD;
          -  Female volunteers in child-bearing age not using adequate means of birth control&#xD;
             (contraceptive pills, Intrauterine devices (IUDs), sterilisation)&#xD;
&#xD;
          -  Pregnancy and/or lactation&#xD;
&#xD;
          -  Known abnormal values of the lab tests (if detected after enrolment, subjects will&#xD;
             continue the treatment provided there are no medical objections)&#xD;
&#xD;
          -  Abnormal values of low density lipoproteins (LDL) and triglycerides (TGL) levels in&#xD;
             blood&#xD;
&#xD;
          -  Participation in another clinical trial within the last 4 weeks and concurrent&#xD;
             participation in another clinical trial&#xD;
&#xD;
          -  Specific dietary requirements that do not allow the volunteers to meet the dietary&#xD;
             guidelines set out for this study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1135/1135.4_U00-0076.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 14, 2014</study_first_submitted>
  <study_first_submitted_qc>July 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2014</study_first_posted>
  <last_update_submitted>July 16, 2014</last_update_submitted>
  <last_update_submitted_qc>July 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

